Fremanezumab-vfrm
Fremanezumab-vfrm Uses, Dosage, Side Effects, Food Interaction and all others data.
Fremanezumab-vfrm is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist ubrogepant, fremanezumab represents an important step forward in the treatment and prevention of migraine headaches.
Fremanezumab-vfrm is a subcutaneous injection that targets the calcitonin gene-related peptide (CGRP) ligand, preventing its binding to the CGRP receptor. It possesses a long duration of action requiring only monthly or quarterly administration and appears well-tolerated in clinical trials.
| Trade Name | Fremanezumab-vfrm |
| Availability | Prescription only |
| Generic | Fremanezumab |
| Fremanezumab Other Names | Fremanezumab |
| Related Drugs | Ajovy, propranolol, atenolol, topiramate, nifedipine, Depakote, verapamil |
| Type | Subcutaneous |
| Weight | 148000.0 Da |
| Protein binding | Data regarding protein binding of fremanezumab are not readily available. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Fremanezumab-vfrm is a humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
Fremanezumab-vfrm is indicated for the preventative treatment of migraine in adults.
Fremanezumab-vfrm is also used to associated treatment for these conditions: Migraine
How Fremanezumab-vfrm works
Studies dating back to 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after administration of antimigraine therapy such as sumatriptan. Moreover, research has shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For these reasons, and despite the fact that their role in migraine headaches has not been entirely elucidated, CGRP and its receptors have become desirable targets for antimigraine therapies. Fremanezumab-vfrm is a humanized monoclonal antibody directed against endogenous CGRP - it interferes with the activity of CGRP, preventing its downstream effects and ultimately mitigating the development of migraine headaches.
Toxicity
Information regarding overdose of fremanezumab is not readily available. The most common adverse events that led to discontinuation of fremanezumab therapy were injection site reactions including erythema, induration, and pain.
Food Interaction
No interactions found.Volume of Distribution
Fremanezumab-vfrm has an apparent volume of distribution of approximately 6 liters which indicates very little distribution into tissue.
Elimination Route
Geometric mean ratios (GMRs) for Cmax for Japanese and Caucasian study subjects were 0.91, 1.04, and 1.14 for 225 mg, 675 mg, and 900 mg doses of fremanezumab . GMRs for AUC (0-inf) were 0.96, 1.09, and 0.98, respectively . Mean Tmax in a range of 5 to 11 days were similar across doses for both ethnicities as well .
Half Life
The mean half-life recorded for fremanezumab was similar across doses for Japanese and Caucasian study subjects and was estimated to be approximately 31-39 days.
Clearance
The apparent clearance of fremanezumab is 0.141 L/day.
Elimination Route
Monoclonal antibody agents like fremanezumab are generally not eliminated via hepatic, renal, or biliary routes.
Innovators Monograph
You find simplified version here Fremanezumab-vfrm
